Anthocyanins Inhibit Nuclear Factor-B 31/05/2010
Multiple effects of anthocyanins inhibiting influenza (flu) virus infectivity 31/05/2010
Cardiovascular study on Medox and cholesterol and CETP 31/05/2010
In spite of the fact that Biolink Group is researching and developing Nutraceuticals in areas with enormous potential in fields like Cardiovascular Diseases we actually consider the potential of lowering Chronic Inflammation (CI) as having the largest health promoting potential and constituting the greatest commercial opportunity.
Furthermore, CI appears to be related to the pathogenesis of about 90 % of all chronic diseases! It is a well-known fact that CI is closely related to the pathogenesis of chronic inflammatory diseases such as cardiovascular diseases, diabetes, Alzheimer’s and many others. Recent medical research has also proven CI to have a rather significant influence on the pathogenesis of cancer.
Initial evidence of the molecular link between inflammation and cancer has been shown by researchers at the University of California, San Diego (UCSD) School of Medicine.
Featured as the cover article in the August 6, 2004 issue of the journal “Cell”, the study also demonstrated that inactivation of a gene involved in the inflammatory process (IKK-ß that normally triggers NF-KB) can dramatically reduce tumor development in mice with a gastrointestinal form of cancer.
A randomized, double blind, placebo-controlled study, involving more than 100 human beings concludes that Medox® lowers chronic inflammation (NF-KappaB), published in the American “The Journal of Nutrition” August 2007.
See also the study based on the Biolink Group anthocyanins, showing that Cyanidin lowers chronic inflammation (NF-KappaB), by influencing the cholesterol efflux, published in the American magazine “Arteriosclerosis, Thrombosis and Vascular Biology” March 14th 2007.
In the US in the year 2000, as an example, more than 80,000,000 people were treated for inflammatory diseases. About 500,000 of these people suffered from very severe side effects. 100,000 were hospitalized due to their use of drugs, and 20,000 of these people died due to medical side effects and complications (Ref: US Arthritis Foundation 2001). These are dramatic figures that are on the increase around the world.
The pharmaceutical industry is struggling (without too much success so far) to bring the market new inflammation fighting drugs, without heavy side effects.
Studies substantiating sensational health promoting effects of Medox® anthocyanins, have been published in different highly respected scientific, internationally recognized nutritional- and medical journals such as:
- ”The Journal of Nutrition”, USA-2007, chronic inflammation
- ”The American Journal of Clinical Nutrition”, USA-2007, vascular diseases, cholesterol, CETP
- ”Clinical Chemistry”, USA-2011, vascular diseases
- ”Arteriosclerosis, Thrombosis and Vascular Biology”, USA-2007, chronic inflammation
- ”The Journal of Federation of American Societies for Experimental Biology”, USA-2004, cancer
- ”The Journal of Lipid Research”, USA-2011, diabetes
- “Molecular and Cellular Biochemistry”, USA-2011, vascular diseases
- "Genes & Nutrition", New York/Heidelberg 2012, cardiovascular diseases